Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial

Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial

The CDK4/6 inhibitor, ribociclib in combination with endocrine therapy significantly improved progression-free survival in the first line setting in post-menopausal patients with HR+/HER2− advanced breast cancer (ABC) in a pivotal phase 3, placebo-controlled trial (MONALEESA-2) and demonstrated supe...

Full description

Bibliographic Details
Main Authors: Borstnar Simona, Palacova Marketa, Łacko Aleksandra, Timcheva Constanta, Gal-Yam Einav Nili, Papazisis Konstantinos, Beniak Juraj, Kudela Pavol, Rubovszky Gábor
Format: Article
Language:English
Published: Sciendo 2022-05-01
Series:Radiology and Oncology
Subjects:
cdk4/6 inhibitor
ribociclib
hr+
her2−
advanced breast cancer
compleement-1 trial
Online Access:https://doi.org/10.2478/raon-2022-0020

Internet

https://doi.org/10.2478/raon-2022-0020

Similar Items